As part of my DPhil I sequenced individual cells from a pre-cancerous condition of the oesophagus called Barrett’s oesophagus and investigated how these cells behave differently to normal upper gastrointestinal cells. As part of a team, I have been able to use the techniques we learned, alongside new single cell sequencing technology, to extend the scope of this project as part of a clinical trial investigating the use of emerging immunochemotherapies in oesophageal cancer treatment. I hope to use these results to help understand why these exciting new treatments work well in some people with oesophageal cancer, and not well in others.
I qualified as a doctor in Liverpool and completed my early surgical training in the Northwest of England before moving to Oxford to undertake a DPhil in upper gastrointestinal single cell RNA-seq, supervised by Xin Lu and Mark Middleton. Since finishing my DPhil, I have completed training as an oesophago-gastric cancer surgeon in Oxford, and continue to participate in oesophago-gastric research between Oxford University Hospitals and the Ludwig Institute.
I have previously been involved in public engagement through supporting science events in local schools, and hope to continue with this.
Delayed Surgical Intervention After Chemoradiotherapy in Esophageal Cancer
Chidambaram S. et al, (2023), Annals of Surgery
p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
Miller P. et al, (2023), Cell Death & Differentiation, 30, 1619 - 1635
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM. et al, (2023), Cancer cell, 41, 1222 - 1241.e7
Multicenter, Prospective Cohort Study of Oesophageal Injuries and Related Clinical Outcomes (MUSOIC study).
Owen RP. et al, (2023), Annals of surgery
Association between epigenetic heterogeneity of esophageal adenocarcinoma and response to first-line immunochemotherapy in LUD2015-005 Trial
Xie PF. et al, (2023), CANCER RESEARCH, 83